Compare Suncor Energy Inc. (SU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Suncor Energy Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Suncor Energy Inc. trades at $72.29 (market cap $82.76B), while Vertex Pharmaceuticals Incorporated trades at $510.6 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Suncor Energy Inc. pays a 2.39% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Suncor Energy Inc. for 57 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SU | VRTX | |
|---|---|---|
Market Cap | $82.76B | $127.55B |
Volume | 3,832,959 | 1,487,944 |
Sector | Energy | Health |
52-Week High | $71.87 | $557.96 |
52-Week Low | $38.17 | $407.37 |
Typical Hold Time | 57 Days | 120 Days |
Enterprise Value | $89.29B | $121.68B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Suncor Energy (SU) trades at $72.17, up 5.91% in the past 24 hours and near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, though the RSI suggests mild overbought conditions. Fundamentally, the company maintains solid profitability with a 14.7% net income margin and a reasonable P/E of 13.46. Recent news highlights asset divestments and a CEO transition, while analyst consensus is strongly positive with 74% buy ratings.
The outlook for SU is favorable, supported by robust cash flow, aggressive shareholder returns, and a discounted valuation relative to peers. Key opportunities include global refining strength and debt reduction, while risks involve commodity price volatility and operational challenges. The stock's momentum and fundamental health suggest potential for continued upside, contingent on stable energy markets and execution of strategic initiatives.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
